Founded in 2014 as an academic spinoff from VU University of Amsterdam, LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), LUMICKS’ tools facilitate the understanding of life to the smallest detail.
Applying and measuring forces and interactions in biology enables real-time analysis of underlying biological mechanisms, building the crucial and yet unfinished bridge between structure and function at the molecular and cellular levels. Using LUMICKS’ groundbreaking C-Trap® Optical Tweezers – Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. The z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. Since its release in 2020, the z-Movi has been adopted by leading biotech and pharmaceutical companies around the world to accelerate the entry of cell therapies into clinical trials.
As the z-Movi platform ramps and C-Trap uptake in the translational research setting grows, LUMICKS is poised to have a measurable impact on the speed-to-market and success rate of a multitude of new therapeutics that treat a range of common and devastating diseases like cancer, infection, and autoimmune disorders.
Company : LUMICKS
Investment type : Growth Equity
Investment date : April 2021
Location : Amsterdam, Netherlands
Website : lumicks.com
“We believe LUMICKS’ z-Movi Cell Avidity Analyzer for direct, high-resolution measurement of cell avidity is a revolutionary platform that can accelerate translational R&D across institutions and biopharma. The z-Movi solution has the potential to drive remarkable advances in cancer treatment. It builds on LUMICKS’ tradition of innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.”
Alex Slack, Founding Partner at Lauxera